ARTICLE | Company News

Mast Therapeutics cardiovascular, hematology news

October 3, 2016 7:00 AM UTC

Mast said it will discontinue clinical development of vepoloxamer ( MST-188) and focus on developing aironite ( AIR001) to treat heart failure with preserved ejection fraction (HFpEF). Last month, Mast reported that vepoloxamer missed the primary endpoint in the Phase III EPIC trial to treat sickle cell disease. The antithrombotic poloxamer that binds to hydrophobic surfaces on damaged cells also was in Phase II testing to treat chronic heart failure. Mast said it is analyzing data from both trials and will "assess opportunities to create value from" vepoloxamer. AIR001, an inhaled nebulized sodium nitrite, is in three investigator-sponsored Phase II trials to treat HFpEF. ...